Drugs for Congestive Heart Failure

Drugs for Congestive
Heart Failure
Dr Lokendra Sharma
Sr. Professor, Pharmacology
SMS Medical College, Jaipur

Basic Definition
Heart failure is a
medical term that
describes an
inability of the
heart to keep up
its work load of
pumping blood to
the lungs and to the
rest of the body.
http://danilhammoudimd_1.tripod.com/cardio1/id57.htm

Classification
I) Drugs with positive inotropic effects-
a) Cardiac glycosides- Digoxin, Digitoxin,
Ouabain
b) Phosphodiesterase inhibitors- Inamrinone,
Milrinone, Levosimendan
c) Beta adrenergic agonist- Dopamine,
Dobutamine, Dobuxamine

II) Drugs without positive inotropic effects-
a) Diuretics- Bumetanide, Furosemide,
Hydrochlorothiazide, Spironolactone
b) ACEIs- Enalapril, Lisinopril, Ramipril
c) Beta-1 adrenoceptor antagonist-
Bisoprolol, Carvedilol, Metoprolol

A, B, C, D, Es of Heart Failure Therapy
A Angiotensin converting enzyme inhibitors
anticoagulants, amiodarone, AICD, assist
devices
B Beta blocking drugs
C Calcium channel blocking drugs, coronary
revascularization, cardiac transplant,
cardiomyoplasty, cardiac reduction surgery
D Diet, diuretics, digitalis, dobutamine
E Exercise

CHF ClassificationNew York Heart Association
Class I - Asymptomatic
Class II - Symptomatic with moderate
exertion
Class III - Symptomatic with mild exertion
Class IV - Symptomatic with no exertion/or
at rest

CHF: Clinical Assessment
Left or right sided
History
– Left sided
• Orthopnea
• Dyspnea
– Right sided
• Anorexia
• Abdominal distension
• Ankle edema
Exam
– Left sided
• Rales
• Narrow pulse pressure
• Increasing S3
– Right sided
• Elevated JVP
• Hepato-jugular reflex
• Loud P2

CHF: Pharmacotherapy
 Relief of symptoms
Diuretics
Digoxin
 Reduction in mortality/hospitalizations
ACE Inhibitors
Beta blockers
Spironolactone
 Rescue in advanced failure
Inotropic infusions (dobutamine)
Vasodilators

Principles in selecting appropriate
medications
Reduction in
Pre-load: Diuretics
After-load: ACE Inhibitors
Filling pressures: Nitrates
Restoring perfusion
Inotropic agents
Beta adrenergic receptor agents: Dobutamine
Phosphodiesterase inhibitors: Milrinone

Compensatory Mechanisms in
Heart Failure
Mechanisms
designed for
acute loss in
cardiac output
Chronic
activation of
these
mechanisms
worsens heart
failure

Potential Therapeutic Targets in
Heart Failure
Preload
Afterload
Contractility

Positive Inotropic Agents
Cardiac Glycosides
Phosphodiesterase inhibitors
 b-adrenoceptor agonists and
dopamine receptor agonists

Cardiac
Glycosides
Digoxin
Digitoxin
Deslanoside
Ouabain

Mechanism of Digitalis Action:
Molecular
Inhibition of
Na/K ATPase
Blunting of Ca2+
extrusion
 Ca2+
i
 Sarcomere
shortening

Effects on Cardiac Function
Positive inotropy
Direct electrophysiological effects
Effects mediated through increased
vagal tone

Direct Electrophysiological
Effects:
Cellular Action Potential

Summary Direct
Electrophysiological Effects
Less negative membrane potential:
decreased conduction velocity
Decreased action potential duration:
decreased refractory period in ventricles
Enhanced automaticity due to
Steeper phase 4
After depolarizations

Parasympathomimetic Effects
Decreased conduction velocity in the
AV node
increased effective refractory period
in the AV
Heart block (toxic concentrations)

EKG Effects of
Digitalis
Decrease in R-T
interval
Inversion of T wave
Uncoupled P waves
(Toxic
concentrations)
Bigeminy (toxic
concentrations)

Summary of Pharmacokinetic
profile of cardiac glycosides

Therapeutic Uses of Digitalis
Congestive Heart Failure
Atrial fibrillation

Overall Benefit of Digitalis to
Myocardial Function
 cardiac output
 cardiac efficiency
  heart rate
  cardiac size
NO survival benefit

Other Beneficial Effects
Restoration of baroreceptor
sensitivity
Reduction in sympathetic activity
Increased renal perfusion, with 
edema formation

Administration
Digoxin has a long enough half life (24-36
hr.) and high enough bioavailability to allow
once daily dosing
Digoxin has a large volume of distribution
and dose must be based on lean body mass
Increased cardiac performance can increase
renal function and clearance of digoxin
Eubacterium lentum

Adverse Effects
Cardiac
AV block
Bradycardia
Ventricular extra systole
Arrhythmias
CNS
GI
Therapeutic index is ~ 2!

Serum Electrolytes Affect
Toxicity
K+
Digitalis competes for K binding at Na/K ATPase
Hypokalemia: increase toxicity
Hyperkalemia: decrease toxicity
Mg2+
Hypomagnesemia: increases toxicity
Ca2+
Hypercalcemia: increases toxicity

Treatment of Digitalis Toxicity
Reduce dose: 1st degree heart block,
ectopic beats
Atropine: advanced heart block
KCl: increased automaticity
Antiarrhythmic: ventricular arrhythmias
Fab antibodies: toxic serum
concentration; acute toxicity

Phosphodiesterase
Inhibitors
 Amrinone
 Milrinone
 levosimendan
Mechanism of Action
 Inhibition of type III phosphodiesterase
 intracellular cAMP
 activation of protein kinase A
 Ca2+ entry through L type Ca2+ channels
 inhibition of Ca2+ sequestration by SR
 cardiac output
  peripheral vascular resistance

Mechanism of action of beta agonists and
PDE isozyme-3 inhibitors in heart failure

Phosphodiesterase Inhibitors:
Therapeutic Use
Short term support in
advanced cardiac failure
Long term use not possible

Adverse Effects of
Phosphodiesterase Inhibitors
Cardiac arrhythmias
GI: Nausea and vomiting
Dose dependent
thrombocytopenia
Sudden death

b-Adrenoceptor and Dopamine
Receptor Agonists
Dobutamine
Dopamine

Mechanism of Action: Dobutamine
Stimulation of cardiac b1-
adrenoceptors: inotropy >
chronotropy
Peripheral vasodilatation
 myocardial oxygen demand

Mechanism of Action: Dopamine
Stimulation of peripheral
postjunctional D1 and
prejunctional D2 receptors
Splanchnic and renal
vasodilatation

Therapeutic Use
Dobutamine: management of acute
failure only
Dopamine: restore renal blood in
acute failure

Dobutamine
 ß-1 receptor agonist
 Low-dose dobutamine (2-3 ug/kg/min)
  myocardial contractility and cardiac output,
arteriovenous dilatation
 High-dose dobutamine (5-15 ug/kg/min)
tachycardia, arrhythmia, splanchnic and renal
vasoconstriction
associated with symptomatic benefit
 Continuous home pump infusion
 T .half life 2 minute

Adverse Effects
Dobutamine
Tolerance
Tachycardia
Dopamine
tachycardia
arrhythmias
peripheral vasoconstriction

Mechanism of Action
Afterload reduction
Preload reduction
Reduction of facilitation of
sympathetic nervous system
Reduction of cardiac
hypertrophy

ACE Inhibitors: Therapeutic
Uses
Drugs of choice in heart failure
(with diuretics)
Current investigational use:
Acute myocardial infarction
AT II antagonists

Diuretics: Mechanism of Action
in Heart Failure
Preload reduction: reduction of excess
plasma volume and edema fluid
Afterload reduction: lowered blood
pressure
Reduction of facilitation of
sympathetic nervous system

Vasodilators
Mechanism of action: reduce
preload and afterload
Drugs used
Sodium nitroprusside
Hydralazine
Ca2+ channel blockers
Prazosin

b-Blockers in Heart Failure:
Mechanism of Action
Standard b-blockers:
Reduction in damaging sympathetic
influences in the heart (tachycardia,
arrhythmias, remodeling)
inhibition of renin release
Carvedilol:
Beta blockade effects
peripheral vasodilatation via a1-
adrenoceptor blockade (carvedilol)

Spironolactone
Aldosterone antagonist, K-sparing diuretic
Prevention of aldosterone effects on:
Kidney
Heart?
Aldosterone inappropriately elevated in CHF
Mobilizes edema fluid in heart failure
Prevention of hypokalemia induced by loop
diuretics (protection against digitalis toxicity?)
Prolongs life in CHF patients

Take Home Message
Diuretics of choice in acute CHF- Loop
diuretic
Short term management of acute CHF- Inotropic
drugs
Cardiac glycosides act by inhibiting Na+ K+
ATPase
Digoxin is only inotropic drug, can be given orally
Thrombocytopenia side effect of Inamrinone
CCBs should not used in CHF – may increase
mortality

Aldosterone antagonist and beta
blocker- reduce the mortality
Widely used beta blocker- Carvedilol
Beta blockers contraindicated in
acute CHF.

Drugs for Congestive Heart Failure

More Related Content

What's hot

Similar to Drugs for Congestive Heart Failure

More from SMS MEDICAL COLLEGE

Recently uploaded

Drugs for Congestive Heart Failure

Editor's Notes